Kayla Simeone
About Kayla Simeone
Kayla Simeone is a Scientist I specializing in Protocol Design and Development at Celerion, with extensive experience in cancer research and development. She holds a Research Doctorate in Molecular Biology from Université de Montréal and has previously worked in various research roles, contributing to advancements in cancer treatment and drug response prediction.
Work at Celerion
Kayla Simeone has been employed at Celerion as a Scientist I in Protocol Design and Development since 2021. In this role, she contributes to the design and execution of scientific protocols, applying her extensive knowledge in clinical and research settings. Her position involves collaboration with cross-functional teams to ensure the successful development of protocols that meet regulatory standards.
Education and Expertise
Kayla Simeone holds a Research Doctorate in Molecular Biology from Université de Montréal, where she studied from 2017 to 2021. Prior to that, she completed her Master's degree in Molecular Biology at the same institution from 2016 to 2017. She also earned a Bachelor's degree in Pharmacology from Université de Sherbrooke from 2012 to 2015. Her educational background provides her with a solid foundation in various scientific disciplines, particularly in cancer biology and treatment.
Background in Research
Kayla Simeone has a diverse background in research, having worked in multiple laboratories. She served as a Master Thesis Student at CRCHUM in the laboratory of Dr. Fred Saad and Dr. Anne-Marie Mes-Masson from 2016 to 2017. Additionally, she completed internships at CHU de Sherbrooke and EURO - PHARM, gaining practical experience in research methodologies and laboratory techniques. Her research has focused on developing ex vivo models for predicting patient responses to cancer therapies.
Achievements in Cancer Research
During her graduate studies, Kayla Simeone developed a solid tumor-derived ex vivo model system aimed at predicting patient responses to drugs in a personalized manner. She has also worked as a TransMedTech and FRQS scholar, focusing on validating a novel tumor-derived model system for predicting responses to both conventional and targeted therapies in cancer treatment. Her research expertise includes ovarian, uterine, and prostate cancer biology.
Language and Communication Skills
Kayla Simeone is fluent in both English and French, which enhances her communication capabilities in diverse professional environments. Her proficiency in these languages allows her to effectively collaborate with colleagues and stakeholders across various regions, contributing to her success in scientific research and development.